nintedanib + gefitinib + erlotinib + afatinib + osimertinib

This is a hypothetical combination of five small molecule tyrosine kinase inhibitors: nintedanib, gefitinib, erlotinib, afatinib, and osimertinib. All five drugs are orally administered and primarily used in the treatment of non-small cell lung cancer (NSCLC), particularly in patients with specific mutations in the epidermal growth factor receptor (EGFR). Nintedanib is a triple angiokinase inhibitor targeting vascular endothelial growth factor receptors (VEGFRs), fibroblast growth factor receptors (FGFRs), and platelet-derived growth factor receptors (PDGFRs). Gefitinib, erlotinib, afatinib, and osimertinb are EGFR tyrosine kinase inhibitors; afatinb irreversibly inhibits EGFR as well as HER2/ErbB2 and HER4/ErbB4. Osimertinb is notable for its activity against T790M resistance mutations in EGFR. This combination has not been described or approved for clinical use as a single regimen; however, individual agents or dual combinations have been studied for advanced NSCLC[1][3][5][6][7].

Brand names

Vargatef

Other names

BIBF 1120 (nintedanib)ZD1839 (gefitinib)OSI-774 (erlotinib)BIBW 2992 (afatinib)AZD9291 (osimertinib)